06-07-06

Express Mail Label No.: EV461506539US

Date of Deposit: June 5, 2006

Attorney Docket No. 22058-590DIV CON

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

LICANT(S):

Hermann et al.

SERIAL NUMBER:

10/614,475

**EXAMINER:** 

Tungaturth, Parithosh K.

FILING DATE:

July 7, 2003

ART UNIT:

1643

For:

CHEMOKINES WITH AMINO-TERMINAL MODIFICATIONS

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

## TRANSMITTAL

Enclosed herewith are the following for the above-identified non-provisional patent application:

- 1. Response to May 5, 2006 Office Action (6 pgs); and
- 2. Return Postcard.

If the enclosed papers are considered incomplete, Applicants request that the Mail Room contact the undersigned collect at telephone number (617) 542-6000.

The Commissioner is authorized to charge any fees that may be required or credit any overpayment of same to Deposit Account No. 50-0311 (Reference No. 22058-590DIV CON).

Respectfully submitted.

Nor R. Elrifi, Reg. No. 39,529 David E. Johnson, Reg. No. 41,874


Attorneys for Applicant

c/o MINTZ LEVIN Tel: (617) 542-6000

Fax: (617) 542-2241

Dated: June 5, 2006 Customer No. 30623

TRA 2159731v.1



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Hermann et al.

SERIAL NUMBER:

10/614,475

**EXAMINER:** 

Tungaturth, Parithosh K.

FILING DATE:

July 7, 2003

ART UNIT:

1643

For:

CHEMOKINES WITH AMINO-TERMINAL MODIFICATIONS

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

## Response to May 5, 2006 Office Action and Supplemental Preliminary Amendment

In response to the Office Action mailed May 5, 2006, Applicants elect the invention of Group I (SEQ ID NO. 1), with traverse. Applicants traverse is that the need for restriction as between any inventions corresponding to SEQ ID NO:1 and SEQ ID NO:3 is now moot because new claim 74 and amended claim 67, from the remaining claims in the application depend, specifies a sequence--amino acids 22-328 of SEQ ID NO:1--that is common to the amino acid sequences of both SEQ ID NO:1 and SEQ ID NO:3.

Amendments to the claims are reflected in the listing of claims, which begins on page 2. Remarks begin on page 6.